PainReform reports 1H EPS ($1.09) vs. ($63.15) last year

Ehud Geller, Chairman and interim CEO of PainReform (PRFX), stated, “The first half of 2025 has been transformational for PainReform as we advanced our dual strategy in specialty pharmaceuticals and renewable energy technologies. On the pharmaceutical side, we strengthened our pipeline with the acquisition of a majority interest in LayerBio and its OcuRing-K platform, a breakthrough ‘dropless’ therapy designed to address post-surgical pain and inflammation following cataract surgery. Together with continued development work on PRF-110, which demonstrated meaningful efficacy in the early part of the postoperative period, we are expanding our portfolio of non-opioid solutions to meet significant clinical needs in large, global markets. In parallel, our DeepSolar division continues to demonstrate strong momentum and commercial promise. Highlights from the first half of the year include the completion of the MyDeepSolar consumer app, acceptance into NVIDIA’s Connect Program to accelerate the development of our DeepSolar Predict forecasting solution, and the successful completion of our 92MW pilot project with Econergy in Romania, which advanced into our first commercial customer agreement. This agreement marks DeepSolar’s transition from pilot stage into its initial phase of commercial deployment. While still in the early stages, this milestone provides a foundation for scaling the platform with additional customers and projects, demonstrating its potential to become a meaningful contributor to long-term growth and shareholder value. At the same time, we are committed to maintaining financial discipline and resource efficiency. Operating expenses declined meaningfully compared to the prior year period, and we significantly reduced our net loss while preserving a solid working capital position. As we pursue growth opportunities, we will continue to balance innovation with careful expense management and sound execution. This prudent approach is central to our strategy of building sustainable value across both our healthcare and clean energy businesses.”